Skip to main content

Table 3 Summary of the sociodemographic characteristics and treatments administered to patients with Behçet’s disease in the RISE (U.S.) registry and studies from endemic regions

From: Epidemiology and treatment of Behçet’s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions

Characteristics Patients with BD in U.S. (RISE) (N = 1323) Patients with BD in Egypt (ECR) [11] (N = 1526) Patients with BD in Turkey [12] (N = 682) Patients with BD in Iran [7] (N = 163) Patients with BD in Japan [13] (N = 135)
Sociodemographic Age, mean (SD) 48.7 (16.3) 35.7 (9.84) 33.0 (9.9) NR NR
Female, N (%) 1049 (79.3) 424 (27.8) 113 (16.6) 63 (38.7) 78 (57.8)
Medications Colchicine, N (%) 728 (55.0) 611 (82.7) 599 (87.8) 108 (66.3) 90 (66.7)
Dapsone, N (%) 62 (4.7) NR NR NR 0 (0.0)
Glucocorticoids, N (%) 895 (67.6) 947 (90.2) 384 (56.3) 110 (67.5) 78 (57.8)
cDMARDs, N (%)      1 (0.70)
Azathioprine, N (%) 418 (31.6) 474 (26.7) 347 (50.8) 48 (29.4) 17 (12.6)
Methotrexate, N (%) 288 (21.8) 67 (7.2) 14 (2.1) 51 (31.3) 9 (6.7)
Hydroxychloroquine, N (%) 117 (8.8) NR NR NR NR
Sulfasalazine, N (%) 53 (4.0) NR 51 (7.5) 3 (5.4) 31 (23.0)
Mycophenolate, N (%) 31 (2.3) NR NR 0 (0.0) 0 (0.0)
Leflunomide 26 (1.9) NR NR NR NR
Cyclosporine, N (%) 23 (1.5) 282 (26.7) 93 (13.6) 13 (8.0) 14 (10.4)
Cyclophosphamide, N (%) < 10 208 (20.1) 39 (5.7) 39 (23.9) 0 (0.0)
Minocycline, N (%) < 10 NR NR NR NR
Tacrolimus, N (%) 11 (0.83) NR NR NR NR
Biologics-TNFi, N (%) 389 (29.4) 83 (8.3) NR 1 (0.60) NR
Infliximab, N (%) 192 (14.5) NR 4 (0.6) NR NR
Adalimumab, N (%) 187 (14.1) NR NR NR 10 (7.4)
Etanercept, N (%) 92 (6.9) NR NR NR 1 (0.70)
Golimumab, N (%) 20 (1.5) NR NR NR 0 (0.0)
Certolizumab, N (%) 30 (2.3) NR NR NR NR
Biologics-non-TNFia, N (%) 59 (4.5) NR NR NR NR
tsDMARDs 53 (4.0) NR NR NR NR
  1. RISE Rheumatology Informatics System for Effectiveness, ECR Egyptian College of Rheumatology, csDMARDs conventional disease modifying anti-rheumatic drugs, TNFi tumor necrosis factor inhibitors, NR non recorded
  2. aBiologics-non-TNFi include rituximab, abatacept, tocilizumab, ustekinumab, and secukinumab